Tracers / [177Lu]Lu-BPAMD
[177Lu]Lu-BPAMD
Also written as [Lu-177]Lu-BPAMD
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated bisphosphonate
- Target / mechanism
- Bone-seeking bisphosphonate with hydroxyapatite affinity for skeletal targeting PMID 41900797
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-bpamd/">ga68-bpamd</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >98% | >98% | BPAMD ABX | 41900797 2026 Pharmaceutics Briefly, 74 MBq of [177Lu]LuCl3 was added in an aqueous solution containing 100 µg of BPAMD in 0.5 mL of sodium acetate buffer (0.4 M, pH 4.5). — Both complexes achieved a radiochemical yield of greater than 98%. |
| — | — | — | almost quantitative | — | BPAMD | 25714451 2015 Cancer Biother Radiopharm An automated synthesis unit was designed for the production of therapeutic doses of [(177)Lu]BPAMD up to 5 GBq. — A Kit formulation combining BPAMD, acetate buffer, and ethanol resulted in almost quantitative labeling yields. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-BPAMD, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 41900797: 'The ligand (4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (BPAMD) was purchased from ABX (Radeberg, Germany).'.